First trimester screening for Down syndrome using free β hCG, total hCG and PAPP-A: An exploratory study

Prenatal Diagnosis

Volumn 27, Issue 12, 2007, Pages 1118-1122

  Wright, Dave ^a   Spencer, Kevin ^b   Nix, Barry ^c  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b KING GEORGE HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Down syndrome; First trimester; Screening

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; CONTROLLED STUDY; DNA SCREENING; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY ANALYSIS;

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; COMPUTER SIMULATION; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FETUS; HUMANS; MONTE CARLO METHOD; PILOT PROJECTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 37049020247     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.1844     Document Type: Article

References (11)

1. Evans MI, Krantz DA, Hallahan TW, Galen RS. 2007. Meta-analysis of first trimester Down syndrome screening studies: free β-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarkers protocol. Am J Obstet Gynecol 196: 198-205.
2. Malone FD, Canick JA, Ball RH, et al. 2005. First trimester or second trimester screening, or both for Down's syndrome. N Engl J Med 353: 2068-2070.
3. Nicolaides KHN, Spencer K, Avgidou K, Faiola S, Falcon O. 2005. Multicenter study of first trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
4. Office for National Statistics. Birth Statistics, Series FM1, Numbers 25-27. HMSO, 2000, 2001, 2002. London.
5. Palomaki GE, Wright DE, Summers AM, et al. 2006. Repeated measurement of pregnancy-associated plasma Protein-A (PAPP-A) in Down syndrome screening: A Validation Study. Prenat Diagn 26: 730-738.
6. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using NT, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
7. Spencer K, Berry E, Crossley JA, Aitken DA, Nicolaides KH. 2000. Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy? Prenat Diagn 20: 311-317.
8. Spencer K, Crossley JA, Nix ABJ, Dunstan FDJ, Williams K. 2002. Temporal changes in maternal serum biochemistry markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 39: 567-576.
9. Spencer K, Crossley JA, Nix ABJ, Dunstan FDJ, Williams K. 2003. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimester of pregnancy on the estimation of individual patient specific risks and detection rates for Down's syndrome. Ann Clin Biochem 40: 219-231.
10. Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. 2003c. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22: 142-148.
11. Wright DE, Bradbury I. 2005. Repeated measures screening for Down's Syndrome. BJOG 112: 80-83.